Cargando…

Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model

Huntington disease (HD) is a neurodegenerative disorder for which new treatments are urgently needed. Pridopidine is a new dopaminergic stabilizer, recently developed for the treatment of motor symptoms associated with HD. The therapeutic effect of pridopidine in patients with HD has been determined...

Descripción completa

Detalles Bibliográficos
Autores principales:	Squitieri, Ferdinando, Di Pardo, Alba, Favellato, Mariagrazia, Amico, Enrico, Maglione, Vittorio, Frati, Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627560/ https://www.ncbi.nlm.nih.gov/pubmed/26094900 http://dx.doi.org/10.1111/jcmm.12604

Ejemplares similares

Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Nitric Oxide Dysregulation in Platelets from Patients with Advanced Huntington Disease
por: Carrizzo, Albino, et al.
Publicado: (2014)

Pridopidine activates neuroprotective pathways impaired in Huntington Disease
por: Geva, Michal, et al.
Publicado: (2016)

DNA instability in replicating Huntington's disease lymphoblasts
por: Cannella, Milena, et al.
Publicado: (2009)

Mitochondrial Respiration Changes in R6/2 Huntington’s Disease Model Mice during Aging in a Brain Region Specific Manner
por: Burtscher, Johannes, et al.
Publicado: (2020)

Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal Models
por: Di Pardo, Alba, et al.
Publicado: (2016)

Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease
por: Di Pardo, Alba, et al.
Publicado: (2013)

Tractography of the Corpus Callosum in Huntington’s Disease
por: Phillips, Owen, et al.
Publicado: (2013)

Metoprolol‐pridopidine drug–drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease
por: Rabinovich‐Guilatt, Laura, et al.
Publicado: (2017)

Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease
por: Waters, Susanna, et al.
Publicado: (2018)

Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Chen, Shujun, et al.
Publicado: (2021)

Glyco-sphingo biology: a novel perspective for potential new treatments in Huntington's disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease
por: Rabinovich‐Guilatt, L., et al.
Publicado: (2015)

De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

Early defect of transforming growth factor β(1) formation in Huntington’s disease
por: Battaglia, Giuseppe, et al.
Publicado: (2011)

Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma
por: Geva, Michal, et al.
Publicado: (2021)

A Rationale for Hypoxic and Chemical Conditioning in Huntington’s Disease
por: Burtscher, Johannes, et al.
Publicado: (2021)

Pridopidine Reverses Phencyclidine-Induced Memory Impairment
por: Sahlholm, Kristoffer, et al.
Publicado: (2018)

Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses
por: Sahlholm, Kristoffer, et al.
Publicado: (2015)

Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [(18)F] fluspidine and [(18)F] fallypride PET study
por: Grachev, Igor D., et al.
Publicado: (2020)

Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon?
por: Migliore, Simone, et al.
Publicado: (2019)

Stimulation of Sphingosine Kinase 1 (SPHK1) Is Beneficial in a Huntington’s Disease Pre-clinical Model
por: Di Pardo, Alba, et al.
Publicado: (2019)

Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

Safer Attitude to Risky Decision-Making in Premanifest Huntington’s Disease Subjects
por: D’Aurizio, Giulia, et al.
Publicado: (2019)

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
por: Kusko, Rebecca, et al.
Publicado: (2018)

Sleep Quality and Related Clinical Manifestations in Huntington Disease
por: Maffi, Sabrina, et al.
Publicado: (2022)

Deep White Matter in Huntington's Disease
por: Phillips, Owen, et al.
Publicado: (2014)

Brain Region and Cell Compartment Dependent Regulation of Electron Transport System Components in Huntington’s Disease Model Mice
por: Burtscher, Johannes, et al.
Publicado: (2021)

Current Diagnostic Methods and Non-Coding RNAs as Possible Biomarkers in Huntington’s Disease
por: Pellegrini, Miguel, et al.
Publicado: (2022)

“Spazio Huntington”: Tracing the Early Motor, Cognitive and Behavioral Profiles of Kids with Proven Pediatric Huntington Disease and Expanded Mutations > 80 CAG Repeats
por: Graziola, Federica, et al.
Publicado: (2022)

Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose
por: Darpo, Borje, et al.
Publicado: (2023)

Motor phenotype is not associated with vascular dysfunction in symptomatic Huntington’s disease transgenic R6/2 (160 CAG) mice
por: Di Pardo, A., et al.
Publicado: (2017)

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

Aripiprazole in the treatment of Huntington’s disease: a case series
por: Ciammola, Andrea, et al.
Publicado: (2009)

Current Pharmacological Management in Juvenile Huntington’s Disease
por: Robertson, Lisa, et al.
Publicado: (2012)

Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study
por: McGarry, Andrew, et al.
Publicado: (2020)

Author Correction: Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease
por: Di Pardo, Alba, et al.
Publicado: (2018)

Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders
por: Di Pardo, Alba, et al.
Publicado: (2018)

Emotion recognition and inhibitory control in manifest and pre-manifest Huntington's disease: evidence from a new Stroop task
por: Hünefeldt, Thomas, et al.
Publicado: (2020)

Tetrabenazine is neuroprotective in Huntington's disease mice
por: Wang, Hongyu, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9lhd93uj4lihe1rnn2g343jl26